So much to take in, but i see:
1. Lots of hard work behind the scenes with minimal costs. Minimising any future dilution for shareholders with extreme efficiency.
2. Mitigating risk in a big way by extensive programs in all 3 pillars.
3. Boosting possible shareholder value at every opportunity, through covering every angle, EM trial yesterday, Breast Cancer trial in Eastern Europe, highly credentialed participants and more.
Its very impressive to me.
Ann: Race Strategic Update March 2021, page-13
-
- There are more pages in this discussion • 507 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3105 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.95 | 7574 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |